Molina Healthcare Surprises with Quarterly Earnings Beat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2026
0mins
Should l Buy MOH?
Source: NASDAQ.COM
Molina Healthcare's stock surged 14.18% to $21.70 on Thursday, reflecting investor enthusiasm following its quarterly results, despite a 3% year-over-year revenue decline to $10.8 billion, indicating strong market confidence in its future potential.
The company reported a non-GAAP net income of $2.35 per share, exceeding analyst expectations of $2.17, showcasing resilience amid challenges such as lower enrollment in the federal Medicaid program and the expiration of a Medicaid contract in Virginia. Management reaffirmed its full-year 2026 guidance, projecting premium revenue of approximately $42 billion, a 2% decline from 2025, demonstrating stability and a positive outlook in a challenging environment.
Molina's ability to exceed earnings expectations despite revenue challenges highlights its operational strength and adaptability. The reaffirmation of guidance suggests that the company is navigating its current difficulties with confidence, which may further bolster investor sentiment moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOH
Wall Street analysts forecast MOH stock price to fall
14 Analyst Rating
3 Buy
9 Hold
2 Sell
Hold
Current: 194.620
Low
155.00
Averages
180.85
High
250.00
Current: 194.620
Low
155.00
Averages
180.85
High
250.00
About MOH
Molina Healthcare, Inc. is a provider of managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces. The Company operates through four segments: Medicaid, Medicare, Marketplace and Other. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. Medicaid provides healthcare and long-term services and support to low-income Americans. Medicare is a federal program that provides eligible persons aged 65 and over, and some disabled persons, with a variety of hospital, medical insurance, and prescription drug benefits. The Marketplace insurance exchanges allow individuals and small groups to purchase federally subsidized health insurance. It arranges healthcare services for its members through contracts with a network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bank of America Upgrades Molina Healthcare to Buy with $250 Price Target
- Rating Upgrade: Bank of America upgraded Molina Healthcare (MOH) from Underperform to Buy and raised its price target from $152 to $250, reflecting confidence in the favorable margin outlook for the company's Medicaid business.
- Profit Outlook Improvement: Analyst Kevin Fischbeck noted that Molina's Medicaid margins are expected to bottom out in 2026, with states gradually adjusting trend and risk pools in 2024/25, indicating a path for margin recovery and future profitability.
- Earnings Per Share Forecast: Assuming the company's long-term targets and normalized margins by 2029, Fischbeck anticipates Molina's earnings per share to improve by over $30 in the next three years, significantly boosting stock potential and attractiveness for investors.
- Market Uncertainty: Despite the large disparities in Medicaid rates and trends, along with uncertainties in other business areas, Fischbeck believes that Molina could conservatively set a 2029 EPS target of $30, nearly double the consensus estimate of $17.32, highlighting its long-term investment value.
See More
Latest Wall Street Rating Updates
- Starbucks Rating Maintained: Morgan Stanley reiterates its overweight rating on Starbucks, indicating that the ongoing debate about the company's earnings power reflects an improving narrative that may attract more investor interest.
- Robinhood Outlook Positive: Bernstein maintains an outperform rating on Robinhood, noting that HOOD stock marked a bottom in Q1 and has started strong in April, suggesting increasing market confidence in its future.
- CoreWeave Price Target Raised: Wells Fargo raises CoreWeave's price target from $125 to $135, believing that the company's leading position in AI infrastructure will allow it to benefit as demand continues to outpace supply.
- Telecom Argentina Upgrade: JPMorgan upgrades Telecom Argentina from neutral to overweight, expecting substantial benefits from market consolidation as the antitrust review of its acquisition of Telefonica Argentina nears completion.
See More
Coty and Others Under Shareholder Investigation
- Shareholder Investigation Initiated: Grabar Law Office is investigating Coty Inc. for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased before November 5, 2025, to seek corporate reforms and fund recovery.
- False Statement Allegations: Coty is accused of making false statements regarding its growth and profitability prospects for fiscal year 2026, particularly in its Consumer Beauty segment, undermining market confidence in its financial health.
- LKQ Corporation Issues: LKQ Corporation faces a similar investigation for failing to disclose risks associated with its $2.1 billion acquisition of Uni-Select, leading to investor misunderstandings about the company's financial strength and growth prospects.
- Healthcare Company Risks: Molina Healthcare is also under investigation for not disclosing adverse information regarding medical cost trends, which could lead to significant cuts in its financial guidance for fiscal year 2025, impacting shareholder trust and investment decisions.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
Molina Healthcare Surprises with Quarterly Results
- Stock Surge: Molina Healthcare's stock surged 14.18% to $21.70 on Thursday, reflecting investor enthusiasm following its quarterly results, despite a 3% year-over-year revenue decline to $10.8 billion, indicating strong market confidence in its future potential.
- Profitability Decline: Molina's net income fell to $120 million ($2.35 per share) from $333 million a year ago, yet analysts had expected a lower adjusted EPS of $2.17, showcasing the company's resilience amid challenges.
- Impact of Membership Decline: The revenue drop was attributed to lower enrollment in the federal Medicaid program and the expiration of a Medicaid contract in Virginia, highlighting the company's reliance on the Medicaid market and the challenges it faces.
- Guidance Maintained: Management reaffirmed its full-year 2026 guidance, anticipating premium revenue of approximately $42 billion, a 2% decline from 2025, and adjusted net income of at least $5 per share, demonstrating stability and a positive outlook in a challenging environment.
See More
Molina Healthcare Surprises with Quarterly Earnings Beat
- Earnings Surprise: Molina Healthcare reported a non-GAAP net income of $2.35 per share, exceeding analyst expectations of $2.17, despite a 3% year-over-year revenue decline to $10.8 billion, demonstrating the company's resilience in challenging times.
- Stock Surge: Following the earnings release, Molina's stock surged by 14%, indicating strong investor confidence in its financial performance, even though total revenue fell short of the consensus forecast of nearly $10.9 billion.
- Impact of Medicaid Membership Decline: The company attributed its revenue drop to lower enrollment in the federal Medicaid program and the expiration of a Medicaid contract in Virginia, highlighting the challenges faced in the competitive health insurance marketplace.
- Guidance Affirmation: Molina's management maintained its full-year 2026 guidance, projecting premium revenue of approximately $42 billion, a 2% decline from 2025, which reflects the company's confidence in navigating a turbulent market environment.
See More
Bank of America Upgrades Molina Healthcare to Buy with $250 Price Target
- Rating Upgrade: Bank of America upgraded Molina Healthcare (MOH) from Underperform to Buy and raised its price target from $152 to $250, reflecting confidence in the favorable margin outlook for the company's Medicaid business.
- Profit Outlook Improvement: Analyst Kevin Fischbeck noted that Molina's Medicaid margins are expected to bottom out in 2026, with states gradually adjusting trend and risk pools in 2024/25, indicating a path for margin recovery and future profitability.
- Earnings Per Share Forecast: Assuming the company's long-term targets and normalized margins by 2029, Fischbeck anticipates Molina's earnings per share to improve by over $30 in the next three years, significantly boosting stock potential and attractiveness for investors.
- Market Uncertainty: Despite the large disparities in Medicaid rates and trends, along with uncertainties in other business areas, Fischbeck believes that Molina could conservatively set a 2029 EPS target of $30, nearly double the consensus estimate of $17.32, highlighting its long-term investment value.
See More
Latest Wall Street Rating Updates
- Starbucks Rating Maintained: Morgan Stanley reiterates its overweight rating on Starbucks, indicating that the ongoing debate about the company's earnings power reflects an improving narrative that may attract more investor interest.
- Robinhood Outlook Positive: Bernstein maintains an outperform rating on Robinhood, noting that HOOD stock marked a bottom in Q1 and has started strong in April, suggesting increasing market confidence in its future.
- CoreWeave Price Target Raised: Wells Fargo raises CoreWeave's price target from $125 to $135, believing that the company's leading position in AI infrastructure will allow it to benefit as demand continues to outpace supply.
- Telecom Argentina Upgrade: JPMorgan upgrades Telecom Argentina from neutral to overweight, expecting substantial benefits from market consolidation as the antitrust review of its acquisition of Telefonica Argentina nears completion.
See More
Coty and Others Under Shareholder Investigation
- Shareholder Investigation Initiated: Grabar Law Office is investigating Coty Inc. for potential breaches of fiduciary duties by its executives, allowing shareholders who purchased before November 5, 2025, to seek corporate reforms and fund recovery.
- False Statement Allegations: Coty is accused of making false statements regarding its growth and profitability prospects for fiscal year 2026, particularly in its Consumer Beauty segment, undermining market confidence in its financial health.
- LKQ Corporation Issues: LKQ Corporation faces a similar investigation for failing to disclose risks associated with its $2.1 billion acquisition of Uni-Select, leading to investor misunderstandings about the company's financial strength and growth prospects.
- Healthcare Company Risks: Molina Healthcare is also under investigation for not disclosing adverse information regarding medical cost trends, which could lead to significant cuts in its financial guidance for fiscal year 2025, impacting shareholder trust and investment decisions.
See More
US Stocks Fluctuate Slightly, Tech Stocks Reach New All-Time Highs
- Tech Stock Surge: The S&P 500 and Nasdaq 100 indices rose by 0.12% and 0.01% respectively on Monday, reaching all-time highs, reflecting strong market optimism regarding AI infrastructure demand, which is expected to boost technology earnings.
- Oil Price Impact: WTI crude oil prices surged over 2%, exerting downward pressure on the market as President Trump canceled negotiations with Iran, raising inflation expectations that could affect the broader economic landscape.
- Rising Treasury Yields: The 10-year Treasury yield increased to 4.337% due to rising inflation expectations from higher oil prices, with markets anticipating the Fed will keep rates unchanged this week while awaiting further developments in oil prices and inflation.
- Health Insurance Stocks Rally: Health insurance stocks such as Centene, Elevance Health, and Humana all rose over 3% on Monday, providing support to the overall market and demonstrating resilience in the sector amid the current economic environment.
See More
Molina Healthcare Surprises with Quarterly Results
- Stock Surge: Molina Healthcare's stock surged 14.18% to $21.70 on Thursday, reflecting investor enthusiasm following its quarterly results, despite a 3% year-over-year revenue decline to $10.8 billion, indicating strong market confidence in its future potential.
- Profitability Decline: Molina's net income fell to $120 million ($2.35 per share) from $333 million a year ago, yet analysts had expected a lower adjusted EPS of $2.17, showcasing the company's resilience amid challenges.
- Impact of Membership Decline: The revenue drop was attributed to lower enrollment in the federal Medicaid program and the expiration of a Medicaid contract in Virginia, highlighting the company's reliance on the Medicaid market and the challenges it faces.
- Guidance Maintained: Management reaffirmed its full-year 2026 guidance, anticipating premium revenue of approximately $42 billion, a 2% decline from 2025, and adjusted net income of at least $5 per share, demonstrating stability and a positive outlook in a challenging environment.
See More
Molina Healthcare Surprises with Quarterly Earnings Beat
- Earnings Surprise: Molina Healthcare reported a non-GAAP net income of $2.35 per share, exceeding analyst expectations of $2.17, despite a 3% year-over-year revenue decline to $10.8 billion, demonstrating the company's resilience in challenging times.
- Stock Surge: Following the earnings release, Molina's stock surged by 14%, indicating strong investor confidence in its financial performance, even though total revenue fell short of the consensus forecast of nearly $10.9 billion.
- Impact of Medicaid Membership Decline: The company attributed its revenue drop to lower enrollment in the federal Medicaid program and the expiration of a Medicaid contract in Virginia, highlighting the challenges faced in the competitive health insurance marketplace.
- Guidance Affirmation: Molina's management maintained its full-year 2026 guidance, projecting premium revenue of approximately $42 billion, a 2% decline from 2025, which reflects the company's confidence in navigating a turbulent market environment.
See More
